IRIS

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer / Sonpavde, G; Necchi, A; Gupta, S; Steinberg, Gd; Gschwend, Je; Van Der Heijden, Ms; Garzon, N; Ibrahim, M; Raybold, B; Liaw, D; Rutstein, M; Galsky, Md. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 16:2(2020), pp. 4359-4368. [10.2217/fon-2019-0611]

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

Necchi A;
2020-01-01
2020
Inglese
FUTURE ONCOLOGY
Future Medicine Ltd.
16
2
4359
4368
10
2-s2.0-85076871464
WOS:000508439200004
31823654
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer / Sonpavde, G; Necchi, A; Gupta, S; Steinberg, Gd; Gschwend, Je; Van Der Heijden, Ms; Garzon, N; Ibrahim, M; Raybold, B; Liaw, D; Rutstein, M; Galsky, Md. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 16:2(2020), pp. 4359-4368. [10.2217/fon-2019-0611]
none
12
info:eu-repo/semantics/article
262
Sonpavde, G; Necchi, A; Gupta, S; Steinberg, Gd; Gschwend, Je; Van Der Heijden, Ms; Garzon, N; Ibrahim, M; Raybold, B; Liaw, D; Rutstein, M; Galsky, M...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/105853
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 84
social impact